Mucin expression and secretion machinery

The mucin expression and secretion machinery refers to the integrated biological system responsible for the synthesis, packaging, and release of mucin glycoproteins, primarily MUC5AC and MUC5B, by goblet cells and submucosal glands (Fahy and Dickey, 2010, New England Journal of Medicine). This machinery is regulated by complex signaling pathways, including the EGFR and IL-13/STAT6 pathways for expression, and the MARCKS-mediated exocytotic pathway for secretion (Davis and Dickey, 2008, Annual Review of Physiology; Green et al., 2011, American Journal of Respiratory Cell and Molecular Biology). In healthy individuals, this system maintains the protective mucus layer essential for mucociliary clearance and innate defense against pathogens and irritants (Fahy and Dickey, 2010). However, in chronic inflammatory airway diseases such as asthma, COPD, and cystic fibrosis, this machinery becomes overactive, leading to mucus hypersecretion and airway obstruction (Takeyama et al., 1999, PNAS). Therapeutic strategies targeting this machinery include inhibiting mucin gene transcription, blocking the intracellular signaling cascades that trigger exocytosis, or physically altering the mucus properties. For example, MARCKS protein inhibitors like BIO-11006 aim to prevent the release of stored mucin granules into the airway lumen (BioMarck Pharmaceuticals, 2023; Green et al., 2011). Understanding this machinery is crucial for developing treatments that can selectively reduce pathological hypersecretion without compromising baseline protective functions.

Other names

Mucus hypersecretion pathwayMucin regulatory networkGoblet cell secretory machineryAirway mucus production system

The machinery is targeted through the inhibition of mucin gene transcription (e.g., via EGFR or IL-13 pathway blockade), the inhibition of MARCKS-mediated granule exocytosis, and the chemical reduction of mucus viscosity through disulfide bond disruption.